JH
Jiangsu Hengrui Pharmaceuticals Co., Ltd. disclosed a 8.2% stake in BRVE
Jiangsu Hengrui Pharmaceuticals Co., Ltd. reported owning 8.2% of Braveheart Bio, Inc. (BRVE) (7,420,091 shares) in a Schedule 13G filed Nov 9, 2026.
A 13G is a passive stake: the holder does not plan to push for changes.
More BRVE insider and Congress trades
- BuyBRVE · Erez Chimovits$34.9MAug 11, 2026
- BuyBRVE · Orbimed Advisors LLC$34.9MAug 11, 2026
- BuyBRVE · AH Bio Fund IV, L.P.$19.8MAug 11, 2026
- BuyBRVE · Forbion Growth Opportunities Fund III Cooperatief U.A.$64.8MAug 7, 2026
- BuyBRVE · Travis Murdoch$1.5MAug 7, 2026
- BuyBRVE · David Charles Lubner$1000KAug 7, 2026